165 related articles for article (PubMed ID: 34964090)
21. Cognitive impairment does not impact sacral neuromodulation implant rates for overactive bladder.
Zillioux J; Lewis KC; Hettel D; Goldman HB; Vasavada SP; Gill BC
Neurourol Urodyn; 2023 Mar; 42(3):623-630. PubMed ID: 36701189
[TBL] [Abstract][Full Text] [Related]
22. Effect of pulse width variations on sacral neuromodulation for overactive bladder symptoms: A prospective randomized crossover feasibility study.
Rueb J; Goldman HB; Vasavada S; Moore C; Rackley R; Gill BC
Neurourol Urodyn; 2023 Apr; 42(4):770-777. PubMed ID: 36840886
[TBL] [Abstract][Full Text] [Related]
23. [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].
Girtner F; Burger M; Mayr R
Urologe A; 2019 Jun; 58(6):634-639. PubMed ID: 31139864
[TBL] [Abstract][Full Text] [Related]
24. What uro-gynecologists should know about sacral neuromodulation (SNM) for the treatment of refractory overactive bladder.
Oelke M; Addali M; Reisenauer C
Arch Gynecol Obstet; 2019 May; 299(5):1243-1252. PubMed ID: 30941558
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder.
Arlandis S; Castro D; Errando C; Fernández E; Jiménez M; González P; Crespo C; Staeuble F; Rodríguez JM; Brosa M
Value Health; 2011; 14(2):219-28. PubMed ID: 21402292
[TBL] [Abstract][Full Text] [Related]
26. SACRAL NEUROMODULATION IN TREATING OVERACTIVE BLADDER PATIENTS - FIRST-TIME APPLICATION IN CROATIA.
Bakula M; Hauptman D; Hudolin T; Škegro SN; Tudor KI; Bakula B; Kaštelan Ž
Acta Clin Croat; 2023 Jul; 62(Suppl2):143-147. PubMed ID: 38966014
[TBL] [Abstract][Full Text] [Related]
27. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
[TBL] [Abstract][Full Text] [Related]
28. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study.
Kaaki B; Gupta D
PLoS One; 2020; 15(7):e0235961. PubMed ID: 32645082
[TBL] [Abstract][Full Text] [Related]
29. Satisfaction with a rechargeable sacral neuromodulation system-A secondary analysis of the ARTISAN-SNM study.
Geynisman-Tan J; Mueller MG; Kenton KS
Neurourol Urodyn; 2021 Jan; 40(1):549-554. PubMed ID: 33326643
[TBL] [Abstract][Full Text] [Related]
30. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System.
Bertapelle MP; Vottero M; Popolo GD; Mencarini M; Ostardo E; Spinelli M; Giannantoni A; D'Ausilio A
World J Urol; 2015 Aug; 33(8):1109-17. PubMed ID: 25218855
[TBL] [Abstract][Full Text] [Related]
31. Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation.
Starkman JS; Duffy JW; Wolter CE; Kaufman MR; Scarpero HM; Dmochowski RR
Int Urogynecol J Pelvic Floor Dysfunct; 2008 Feb; 19(2):277-82. PubMed ID: 17671752
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder.
Leong RK; de Wachter SG; Joore MA; van Kerrebroeck PE
BJU Int; 2011 Aug; 108(4):558-64. PubMed ID: 21166750
[TBL] [Abstract][Full Text] [Related]
33. Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device.
Zhang Y; Zhang P; Tian X; Chen G; Li Y; Zhang Y; Xu Z; Wei Z; Zhang W; Ma L; Shi B; Liao L; Wang J
World J Urol; 2019 Nov; 37(11):2481-2492. PubMed ID: 30809700
[TBL] [Abstract][Full Text] [Related]
34. [Functional results and satisfaction in 44 patients after implantation of a NS3-type sacral neurostimulator for refractory idiopathic overactive bladder followed at 43 months, single-center series].
Msika J; Kalantan M; Larre S; Leon P
Prog Urol; 2021 Oct; 31(12):725-731. PubMed ID: 33962849
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the efficacy of sacral neuromodulation in the treatment of voiding dysfunction after endometriosis surgery.
Aublé A; Gazdovich S; Dégremont S; Pfister C; Roman H; Bridoux V; Leroi AM; Cornu JN
Prog Urol; 2023 Dec; 33(17):1073-1082. PubMed ID: 37951811
[TBL] [Abstract][Full Text] [Related]
36. [Sacral neuromodulation for refractory overactive bladder].
van Ophoven A
Urologe A; 2018 Nov; 57(11):1375-1388. PubMed ID: 30310935
[TBL] [Abstract][Full Text] [Related]
37. The role of neuromodulation in patients with neurogenic overactive bladder.
Lay AH; Das AK
Curr Urol Rep; 2012 Oct; 13(5):343-7. PubMed ID: 22865208
[TBL] [Abstract][Full Text] [Related]
38. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.
Tilborghs S; De Wachter S
Expert Rev Med Devices; 2022 Feb; 19(2):161-187. PubMed ID: 35061951
[TBL] [Abstract][Full Text] [Related]
39. Sacral Neuromodulation with the InterStim System for Overactive Bladder: 3-Year Results from the French Prospective, Multicenter, Observational SOUNDS Study.
Chartier-Kastler E; Normand LL; Ruffion A; Saussine C; Braguet R; Rabut B; Ragni E; Perrouin-Verbe MA; Pierrevelcin J; Rousseau T; Gamé X; Tanneau Y; Dargent F; Biardeau X; Graziana JP; Stoica G; Brassart E; Fourmarier M; Yaghi N; Capon G; Ferchaud J; Berrogain N; Peyrat L; Pecoux F; Bryckaert PE; Melotti A; Abouihia A; Keller DUJ; Cornu JN
Eur Urol Focus; 2022 Sep; 8(5):1399-1407. PubMed ID: 34334342
[TBL] [Abstract][Full Text] [Related]
40. Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis.
Yang G; Xu Y; Qu G; Zhang Y
PLoS One; 2020; 15(3):e0230355. PubMed ID: 32226049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
